Early Infantile Epileptic Encephalopathy (EIEE), also known as Ohtahara Syndrome, is a severe neurological condition characterized by frequent seizures and significant developmental delays. These seizures typically begin in the first few months of life and are often resistant to treatment. Due to its genetic underpinnings, understanding the specific genetic mutations involved can be crucial for diagnosis, management, and treatment planning.
The Early Infantile Epileptic Encephalopathy Gene Panel Test is a comprehensive diagnostic tool designed to identify genetic mutations associated with EIEE. By analyzing a broad array of genes known to be linked to this condition, the test provides valuable insights that can guide medical professionals in tailoring the most effective treatment strategies for each individual patient.
Administered at DNA Labs UAE, a leading facility in genetic testing, the test ensures high accuracy and reliability. The test cost is set at 7200 AED, reflecting the extensive analysis and expert interpretation involved in identifying the genetic factors contributing to the condition. Through this test, families and healthcare providers can gain a deeper understanding of the disorder, paving the way for personalized treatment approaches and improved outcomes for affected infants.
The Clinical Exome Trio Sequencing Test is a comprehensive genetic screening process designed to identify the genetic causes of inherited diseases within a family. Conducted at DNA Labs UAE, this advanced diagnostic test involves sequencing the exomes—the parts of the genome that encode proteins—of three individuals, typically the child and both parents. This trio approach significantly enhances the ability to pinpoint disease-causing mutations by comparing the child's genetic information with that of the parents, thereby offering insights into the inheritance patterns and potential genetic disorders.
The test is particularly useful in cases where a child presents with symptoms of a genetic disorder that has not been diagnosed through other means. It can identify mutations in over 20,000 genes, covering a vast array of inherited conditions, including rare diseases that may not be detected through standard genetic tests. The Clinical Exome Trio Sequencing Test is invaluable for families seeking answers to complex genetic health puzzles, offering a pathway to targeted treatment options and personalized medical care.
The cost of the Clinical Exome Trio Sequencing Test at DNA Labs UAE is 12,000 AED. This investment covers the comprehensive analysis and detailed reporting necessary to understand the genetic underpinnings of inherited conditions, making it a critical step for families in pursuit of diagnosis, informed decision-making, and management of genetic disorders.
The Oncomine Breast cfTNA Assay Test is a cutting-edge diagnostic tool designed for the detection and analysis of circulating free tumor nucleic acids (cfTNA) in the plasma of patients with breast cancer. This highly sensitive and specific assay is utilized to identify and quantify genetic mutations and alterations in breast cancer DNA, providing critical insights that can guide personalized treatment strategies.
Performed at DNA Labs UAE, a leading facility in genetic testing and analysis, the Oncomine Breast cfTNA Assay Test harnesses next-generation sequencing technology to offer a comprehensive genomic profile of a patient's breast cancer. This non-invasive approach allows for the monitoring of disease progression and response to treatment without the need for traditional, more invasive biopsy methods.
The cost of the Oncomine Breast cfTNA Assay Test at DNA Labs UAE is 9600 AED. While the price may seem high, the value it provides in terms of precise cancer characterization and the potential to tailor treatment plans to individual genetic profiles makes it a valuable tool in the fight against breast cancer. This test represents a significant advancement in oncology, offering hope for improved outcomes through personalized medicine.
The Oncomine Focus Panel and PD-L1 Test, offered by DNA Labs UAE for a cost of 10,500 AED, represents a cutting-edge approach in the field of precision medicine, specifically designed to cater to patients with various types of cancer. This comprehensive test combines the strengths of the Oncomine Focus Panel, which utilizes next-generation sequencing technology to identify key genetic alterations across a wide array of cancer-related genes, with the PD-L1 test that measures the expression of the PD-L1 protein in cancer cells.
The Oncomine Focus Panel targets a curated list of genes associated with cancer, enabling clinicians to pinpoint specific mutations and alterations that could influence treatment decisions. By identifying these genetic markers, healthcare providers can recommend more personalized and effective therapy options for patients, such as targeted therapies or immunotherapies that are best suited to their genetic profile.
The PD-L1 test adds another layer of precision by assessing the level of PD-L1 expression, a protein that plays a crucial role in suppressing the immune response against cancer cells. High levels of PD-L1 on tumor cells may indicate that certain immunotherapies, which block the PD-L1 pathway and thus boost the immune system's ability to fight cancer, could be particularly beneficial for the patient.
Conducted at the state-of-the-art facilities of DNA Labs UAE, this combined testing approach offers a robust tool in the personalized treatment of cancer, aiming to improve outcomes by tailoring therapies to the unique genetic makeup of each patient's tumor.
The Oncomine Lung cfTNA Cancer Panel Test, available at DNA Labs UAE for a cost of 10,500 AED, is a highly advanced diagnostic tool designed for the detection and analysis of circulating free tumor nucleic acids (cfTNA) in the blood of patients suspected to have lung cancer. This non-invasive test utilizes next-generation sequencing (NGS) technology to identify genetic mutations and alterations in cfTNA that are associated with lung cancer. By analyzing a simple blood sample, the test can provide critical information on the genetic makeup of lung tumors, aiding clinicians in making more informed decisions regarding treatment strategies. This approach not only offers a convenient alternative to traditional tissue biopsies but also enables the monitoring of tumor dynamics and resistance mechanisms over time. DNA Labs UAE, by offering this cutting-edge test, demonstrates its commitment to providing state-of-the-art diagnostic solutions to improve patient care and outcomes in the fight against lung cancer.
The Oncomine Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) Test is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to assess two critical biomarkers in cancer patients: Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). This test is pivotal in the realm of precision medicine, as it helps in identifying the genetic alterations within tumors, thereby guiding oncologists in tailoring the most effective treatment strategies for individual patients.
TMB is a measure of the number of mutations within a tumor's DNA, which can be indicative of how well a patient might respond to certain immunotherapies. A high TMB can suggest a tumor is more likely to respond to these treatments. On the other hand, MSI is a condition that occurs due to the failure of the DNA mismatch repair system, leading to increased mutations. It is particularly prevalent in certain types of cancers, such as colorectal cancer, and its presence can also influence treatment decisions, including the use of immunotherapy.
The test is conducted through a sophisticated genomic sequencing process, analyzing a comprehensive panel of genes associated with various cancers to determine the TMB and MSI status. The cost of the test at DNA Labs UAE is 10,500 AED, reflecting the advanced technology and expertise required to perform this intricate analysis. By providing a detailed genetic profile of a patient's tumor, the Oncomine TMB and MSI Test plays a crucial role in advancing personalized cancer care, offering hope for more effective and targeted treatment options.
The Wilson Disease ATP7B Gene Mutation Detection Test is a specialized diagnostic procedure aimed at identifying mutations in the ATP7B gene, which are responsible for Wilson Disease. Wilson Disease is a rare genetic disorder that leads to excessive accumulation of copper in the body, affecting the liver, brain, and other vital organs. Early detection and treatment are crucial for managing the disease effectively.
This test is conducted by DNA Labs UAE, a leading facility in genetic testing, ensuring high accuracy and reliability of results. By analyzing the patient's DNA, the test can pinpoint specific mutations in the ATP7B gene, confirming the diagnosis of Wilson Disease. This information is vital for clinicians to devise appropriate treatment plans and for affected families to understand the risk of inheritance.
The cost of the Wilson Disease ATP7B Gene Mutation Detection Test at DNA Labs UAE is 10,500 AED. Although the price may seem high, the test offers invaluable insights into managing and treating a potentially life-threatening condition, making it a critical investment in the health and well-being of individuals at risk for or suspected of having Wilson Disease.
Autoimmune Cerebellar Ataxia Panel Test is a specialized diagnostic examination designed to identify the presence of specific antibodies that may contribute to autoimmune cerebellar ataxia, a condition where the immune system mistakenly attacks the cerebellum, part of the brain that controls coordination and balance. This comprehensive panel aims to facilitate the accurate diagnosis of autoimmune-related cerebellar ataxia, distinguishing it from other types of ataxia caused by genetic factors, toxins, or other diseases. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expertise in genetic and autoimmune disorders, the test costs 11,790 AED. By pinpointing the exact antibodies causing the immune response, healthcare providers can tailor treatment plans more effectively, offering hope for improved management of symptoms and quality of life for affected individuals.
The Lung Cancer Panel 8 EGFRBRAFALKROSMETPDL1 Test is a comprehensive diagnostic tool designed to identify genetic mutations and markers associated with lung cancer. This advanced panel test targets specific genes such as EGFR, BRAF, ALK, ROS, MET, and the protein PD-L1, which are critical in the development, progression, and treatment response of lung cancer. By analyzing these genetic components, the test aids in the personalization of treatment plans, allowing for targeted therapies that can significantly improve patient outcomes.
Performed at DNA Labs UAE, a leading facility in genetic testing and analysis, this test represents a significant advancement in the field of oncology. The cost of the Lung Cancer Panel 8 Test is 8000 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed. By providing detailed insights into the genetic underpinnings of an individual's lung cancer, the test supports more informed decision-making in treatment planning, potentially leading to more effective management of the disease.
The Oncomine Focus Panel Test, offered at DNA Labs UAE for a cost of 9000 AED, is a state-of-the-art genetic test designed to identify specific mutations in cancer cells. This targeted sequencing panel is utilized to analyze a select set of genes that are known to be involved in various types of cancers. By pinpointing these genetic alterations, the test aids oncologists in developing personalized treatment plans for patients, potentially improving outcomes and minimizing unnecessary treatments. DNA Labs UAE, equipped with advanced genomic technologies, ensures precise and reliable results, making the Oncomine Focus Panel Test a valuable tool in the field of precision oncology.
